Forge Biologics is a cell and gene therapy–focused CDMO working to find disease-modifying, adeno-associated, virus–based therapies to treat rare genetic diseases. Forge Biologics provides end-to-end manufacturing and production to minimize the need for bridging studies. This in turn helps improve their developmental capabilities with viral vectors in order to accelerate gene therapy programs from the preclinical stage through clinical and onto cGMP manufacturing with reduced risks. The company’s viral vector production offers a higher level of vector purity production through chromatography-based purification.